Overview

* Rubicon Organics Q3 2025 revenue up 16% yr/yr, slightly missing analyst expectations

* Company achieved Q3 2025 adjusted EBITDA of C$1.7 mln

* Obtained Health Canada license for Cascadia Facility, operations to begin soon

Outlook

* Company forecasts full-year growth in net revenue and Adjusted EBITDA for 2025

* Rubicon expects Cascadia Facility revenue in first half of 2026

* Company anticipates Cascadia Costs will impact 2025 financial results

Result Drivers

* OPERATIONAL SCALE - Rubicon attributes revenue growth to benefits of operational scale and disciplined cost control

* CASCADIA FACILITY - Health Canada license obtained for Cascadia Facility, expected to expand production capacity by over 40%

* MARKET SHARE - Achieved notable market share in premium cannabis segments, including #1 topical SKU

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight C$15.60 C$15.70

Revenue Miss* mln mln (2

Analysts

)

Q3 C$1.70

Adjusted mln

EBITDA

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Rubicon Organics Inc ( ROMJF ) is C$1.15, about 55.7% above its November 12 closing price of C$0.51

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)